leadf
logo-loader
viewIncanthera Ltd

Incanthera receives positive data skin sensitisation study of skin cancer technology Sol

The specialist oncology firm said it is delighted with the results, which demonstrate that Sol is "non-irritant”

Incanthera Ltd - Incanthera receives positive data skin sensitisation study of skin cancer technology Sol

Incanthera PLC (AQSE:INC) has received positive data from a skin sensitisation study of its Sol skin cancer technology, which demonstrate it is “non-irritant”.

Sol is a proprietary topical formulation designed to deliver an active agent into the skin that is known to prevent the formation of solar (actinic) keratosis and skin cancer.

READ: Incanthera delighted as Sol outshines rivals in new study

Studies carried out in collaboration between XCellR8 and Cutest, a clinical research organisation with expertise in trials using topical applications, have demonstrated “very good correlation” between results using the methodology of this study and those obtained in clinical mildness studies.

Sol's "non-irritancy" was found to be comparable to baby sun protection products tested previously, Incanthera said, with Sol scoring better than products that would be defined as "very mild".

The specialist oncology firm said it is delighted with the results, providing a further valuable marker of the asset and this technology.

“This additional positive data on Sol greatly enhances the product's overall profile and supports our ongoing negotiations with potential commercial partners,” said chairman Tim McCarthy in a statement.

Quick facts: Incanthera Ltd

Price: 17 GBX

AQSE:INC
Market: AQSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera Ltd named herein, including the promotion by the Company of Incanthera Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Incanthera believe new skin cancer prevention cream reveals 'all positives...

Incanthera PLC's (AQSE:INC) CEO Simon Ward and Kevin Hammond talk to Proactive London's Katie Pilbeam about new positive data from new skin permeation and sensitisation studies of its Sol skin cancer technology. Both Simon and Kevin explain that Sol is a cream designed to deliver an active...

2 weeks ago

2 min read